Scarica l'app Stockscreener
261.41
5.02%
12.50
Dopo l'orario di chiusura:
262.00
0.59
+0.23%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KRYS Giù?
Forum
Previsione
Krystal Biotech Inc Borsa (KRYS) Ultime notizie
Krystal Biotech (KRYS) Rises on Positive Phase 1 Data for Cystic Fibrosis Treatment - GuruFocus
KRYS: TD Cowen Raises Price Target and Maintains Buy Rating | KR - GuruFocus
Krystal Biotech stock hits all-time high at 265.99 USD By Investing.com - Investing.com Canada
Citigroup Raises Price Target for Krystal Biotech (KRYS) to $320 - GuruFocus
Recent Price Trend in Krystal Biotech (KRYS) is Your Friend, Here's Why - Yahoo Finance
Krystal Biotech stock maintains Overweight rating at Cantor Fitzgerald - Investing.com
Krystal Biotech stock maintains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Australia
KRYS: HC Wainwright & Co. Raises Price Target to $310 | KRYS Sto - GuruFocus
Krystal Biotech stock price target raised to $288 from $272 at BofA - Investing.com UK
Jefferies raises Krystal Biotech stock price target to $310 on CF data By Investing.com - Investing.com South Africa
Jefferies raises Krystal Biotech stock price target to $310 on CF data - Investing.com India
Assessing Krystal Biotech (KRYS) Valuation As Investors Await CORAL-1 KB407 Interim Cystic Fibrosis Data - Sahm
Krystal Biotech Touts Positive KB407 CF Gene Therapy Data, Eyes Repeat Dosing and Registrational Path - Yahoo Finance
Can Krystal Biotech Inc. stock continue upward trend2025 Support & Resistance & Risk Managed Investment Signals - ulpravda.ru
Will Krystal Biotech Inc. stock benefit from upcoming earnings reportsJuly 2025 Drop Watch & Low Risk Growth Stock Ideas - ulpravda.ru
Will Krystal Biotech Inc. stock benefit from AI adoptionLong Setup & High Accuracy Investment Signals - ulpravda.ru
Krystal Biotech advances KB407 with positive CF trial data - TipRanks
What Wall Street predicts for Krystal Biotech Inc. stock priceJuly 2025 Opening Moves & Free Technical Confirmation Trade Alerts - ulpravda.ru
Krystal Biotech (KRYS) Reports Promising Interim Results from CORAL-1 Study - GuruFocus
Krystal Biotech, Inc. Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study - TradingView — Track All Markets
Will Krystal Biotech Inc. stock reach all time highs in 2025Portfolio Value Summary & Real-Time Market Trend Scan - ulpravda.ru
Krystal Biotech confirms CFTR delivery in CF patients with KB407 By Investing.com - Investing.com India
Krystal Biotech confirms CFTR delivery in CF patients with KB407 - Investing.com
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis - Stock Titan
Trend Recap: Will Krystal Biotech Inc. stock reach all time highs in 2025 - ulpravda.ru
How Krystal Biotech Inc. (4KB) stock responds to bond marketWeekly Gains Summary & Fast Moving Market Watchlists - ulpravda.ru
KRYS Stock Surges 57% in a Year: More Upside Potential in 2026? - Finviz
Krystal Biotech to share interim results from cystic fibrosis trial By Investing.com - Investing.com Nigeria
Krystal Biotech Announces Investor Conference Call for Interim Clinical Update on KB407 in Cystic Fibrosis Study - Quiver Quantitative
Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis - The Manila Times
Citigroup Upgrades Krystal Biotech (KRYS) - Nasdaq
Krystal Biotech (KRYS) Receives Upgraded Rating and Price Target Boost from Citigroup | KRYS Stock News - GuruFocus
Krystal Biotech Shares Rise After Citigroup Upgrade - MarketScreener
Citigroup Upgrades Krystal Biotech to Buy From Neutral, Adjusts Price Target to $309 From $198 - marketscreener.com
VIRGINIA RETIREMENT SYSTEMS ET Al Sells 5,800 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Shareholders Have Earned a 30% CAGR Over the Last Five Years - 富途牛牛
Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference - The Globe and Mail
Krystal Biotech, Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 - Quiver Quantitative
Will Krystal Biotech Inc 4KB stock outperform global peersPortfolio Update Report & Daily Entry Point Alerts - moha.gov.vn
Krystal Biotech Inc Stock Analysis and ForecastVolume Analysis Techniques & Hedge Fund-Style Analysis Now Free - earlytimes.in
Growth Value: Can Krystal Biotech Inc stock deliver surprise earnings beatM&A Rumor & Fast Gaining Stock Reports - moha.gov.vn
Discipline and Rules-Based Execution in KRYS Response - Stock Traders Daily
Rally Mode: Can Krystal Biotech Inc stock continue upward trendJuly 2025 Fed Impact & AI Powered Buy/Sell Recommendations - moha.gov.vn
Exploring High Growth Tech Stocks In The US For December 2025 - simplywall.st
Krystal Biotech (NASDAQ:KRYS) Sets New 52-Week HighWhat's Next? - MarketBeat
Bearish Setup: Can Krystal Biotech Inc stock continue upward trend2025 Historical Comparison & Safe Entry Momentum Tips - moha.gov.vn
Krystal Biotech, Inc. (KRYS) Stock Analysis: Navigating a $7.31 Billion Market Cap with Promising Genetic Medicines - DirectorsTalk Interviews
Krystal Biotech Earnings Notes - Trefis
Krystal Biotech announces resignation of longtime board member - TipRanks
Krystal Biotech Announces Board Resignation - TradingView — Track All Markets
Krystal Biotech, Inc. Announces Resignation of Kirti Ganorkar as Director, Effective December 31, 2025 - marketscreener.com
Krystal Biotech, Inc. $KRYS Shares Purchased by Voya Investment Management LLC - MarketBeat
Krystal Biotech stock hits all-time high at 248.82 USD By Investing.com - Investing.com Nigeria
Krystal Biotech (NASDAQ:KRYS) Hits New 52-Week HighShould You Buy? - MarketBeat
Krystal Biotech stock hits all-time high at 248.82 USD - Investing.com
Trading the Move, Not the Narrative: (KRYS) Edition - Stock Traders Daily
Why Krystal Biotech Inc. stock remains on buy listsWeekly Risk Report & Real-Time Market Sentiment Reports - Улправда
AI Stocks: Will Krystal Biotech Inc. (4KB) stock profit from AI boomPortfolio Performance Summary & Daily Chart Pattern Signal Reports - Улправда
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):